Weigh! Announcement of the regular access list of national medical insurance drug catalog in 2019

[industry trends of pharmaceutical network] on April 17 this year, the state health insurance bureau released the work plan for the adjustment of the national medical insurance drug catalog 2019 According to the schedule of the work plan, the new version of the medical insurance catalog was originally planned to be released in July this year, but there was no news Now, the new health care catalog is finally coming! On August 20, the state health insurance bureau issued the national directory of drugs for basic medical insurance, work injury insurance and maternity insurance (hereinafter referred to as the "drug directory"), and published the 2019 version of the national directory of drugs for basic medical insurance, work injury insurance and maternity insurance The catalogue of drugs is divided into five parts: ordinary medicine, western medicine, Chinese patent medicine, negotiation medicine and Chinese herbal pieces There are 2643 drugs in the regular access part of this release, including 1322 western drugs and 1321 Chinese patent drugs (including 93 national drugs); Chinese herbal pieces are managed by the access method, including 892 In addition, there are 640 class a drugs in the catalogue, including 398 western drugs and 242 Chinese patent drugs Compared with the 2017 version of the medical insurance catalog, the number of class a drugs included in the catalog increased by 46 The transfer of the new version of "drug catalog", which is of more concern to the industry, into and out of the drug list was determined by the voting results of the selection experts Nearly 5000 medical experts participated in the voting, randomly selected from 24 provinces across the country Among them, in terms of drug transfer out, a total of 150 varieties of 2019 version of the directory have been transferred out, including drugs whose number has been cancelled by the drug administration, whose clinical value is not high, whose abuse is obvious and there are better substitutes It is reported that at the media briefing on the adjustment of national medical insurance drug catalog in 2019 held by the State Medical Insurance Bureau, experts focused on referring to the list of national key monitoring drugs for rational use issued by the state health and Health Commission in June, and decided to transfer out all the key monitoring drugs in the national medical insurance drug catalog after evaluation Among the 150 varieties transferred out, it can also be seen that 20 key monitored varieties released by the national health and Health Commission in June this year have been transferred out, in addition to some large varieties with high sales volume In terms of drug transfer, the new medical insurance catalogue will include 128 drugs into the scope of access to be negotiated, including 109 Western medicines and 19 Chinese patent medicines Specifically, it includes antitumor drugs such as trastuzumab, enrotinib, xidaban, as well as cardiovascular system drugs such as recombinant human brain natriuretic peptide and alisartan ester At the same time, there are also compound Huangdai tablets, astragalus polysaccharide for injection and other traditional Chinese medicine for cancer It is reported that the adjustment of drugs is mainly based on the results of expert review and voting selection of some drugs with high clinical value but high price or great impact on the fund, which will be included in the scope of access to be negotiated after preliminary determination The 128 drugs transferred in this time are those that have the intention to be included in the medical insurance catalogue at the national level, but will be officially included in the medical insurance catalogue and the price will be determined depending on the negotiation results Its treatment mainly involves cancer, rare diseases and other major diseases, as well as hepatitis C, hepatitis B, hypertension, diabetes and other chronic diseases In addition, some products are new drugs approved by the State Food and Drug Administration in recent years, including major innovative drugs in China It is reported that in the next step, after confirming the negotiation intention of the enterprise, the negotiation will be organized according to relevant procedures, and the successful negotiation will be included in the catalogue It is also revealed that the new version of the medical insurance catalogue is expected to be officially implemented on January 1, 2020 after the next adjustment of different regions At the same time, the state health insurance bureau will also strengthen the monitoring of the new key varieties and strengthen the post access management.